Is Synchrony Financial (SYF) A Bargain On Its Stripe CareCredit Expansion?

What the new Stripe integration could mean for Synchrony stock

Synchrony Financial (SYF) has drawn fresh attention after announcing a new integration with Stripe that brings its CareCredit financing into Stripe’s online checkout for U.S. health and wellness providers.

The partnership lets existing and new Stripe health and wellness users activate CareCredit directly in their Stripe Dashboard, without extra integrations. That creates a single hub for payment methods, reporting, reconciliation, and chargebacks.

More than 12 million existing CareCredit cardholders, along with newly approved applicants, gain more places to use their card for health and wellness purchases through participating Stripe providers. Customers can also apply for CareCredit during checkout, which may influence how often CareCredit is considered at the point of sale.

For Synchrony, the move keeps CareCredit embedded in platforms that providers already rely on. Investors watching Synchrony stock can now assess this new distribution channel alongside the company’s broader position in consumer credit and healthcare financing.

See our latest analysis for Synchrony Financial.

Synchrony Financial’s share price has climbed 8.32% over the past month and 12.41% over the past quarter to US$78.47, while the 1 year total shareholder return of 10.25% points to momentum that contrasts with a weaker year to date share price move.

If you are weighing how this Stripe partnership fits into a broader set of opportunities in finance and technology, it can be helpful to scan other fast evolving segments through the Simply Wall St screener for 18 top founder-led companies

Synchrony Financial shares have run ahead of the broader story, yet the stock still sits below both analyst targets and some fair value estimates. Is this gap a real opportunity or a warning sign before the valuation section?

Most Popular Narrative: 12% Undervalued

The most followed narrative currently points to a fair value of $89.22 for Synchrony Financial, compared with the last close at $78.47. That gap rests on a specific view of future revenue, earnings, and the discount rate applied to those cash flows.

The company's expansion in high-growth verticals like health, wellness, and pet financing, where it is resuming growth after recent credit tightening, broadens the consumer base and diversifies revenue streams. This is seen as contributing to more sustainable earnings growth and risk mitigation over the long run.

Read the complete narrative.

Want to see what sits behind that health and wellness push? The narrative leans heavily on future revenue expansion, slimmer margins, and a higher earnings multiple. Curious which exact assumptions need to hold for that to support a higher fair value? The full breakdown joins those moving parts into one valuation story.

Result: Fair Value of $89.22 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that narrative around Synchrony Financial can be challenged if key retail partners reset terms, or if fintech competitors pull spending away from traditional credit products.

Find out about the key risks to this Synchrony Financial narrative.

Next Steps

With both risks and rewards in the picture for Synchrony Financial, it makes sense to move quickly and test the story against your own view by reviewing the 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond Synchrony Financial?

If you stop with Synchrony Financial, you could miss other opportunities that fit your style. Use the Simply Wall St screener to quickly spot ideas worth deeper work.

• Target steady compounding by checking companies with resilient payouts using the 8 dividend fortresses.
• Hunt for quality at a markdown by scanning the 49 high quality undervalued stocks.
• Prioritise capital preservation and smoother returns by reviewing the 85 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com